Verition Fund Management
GLUE icon

Verition Fund Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Verition Fund Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-51,725
Closed -$240K – 3721
2025
Q1 		$240K Buy
+51,725
New +$317K ﹤0.01% 2970
2023
Q4 		– Sell
-13,127
Closed -$62.9K – 2467
2023
Q3 		$62.9K Buy
+13,127
New +$84.5K ﹤0.01% 2164

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Verition Fund Management's GLUE Position: Q2 2025 in Review

Verition Fund Management sold out of Monte Rosa Therapeutics (GLUE) in Q2 2025, closing a stake of 51,725 shares — an estimated $240K sold.

Verition Fund Management first reported a position in GLUE in Q3 2023 and held it in 2 quarters. The position peaked at $240K in Q1 2025. 116 funds tracked by Wall St. Rank hold GLUE as of Q2 2025.

  • Verition Fund Management reported no remaining Monte Rosa Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Verition Fund Management sold 51,725 Monte Rosa Therapeutics shares in Q2 2025, an estimated $240K.
  • Verition Fund Management first reported a position in Monte Rosa Therapeutics in Q3 2023 and held it in 2 quarters.
  • Verition Fund Management's Monte Rosa Therapeutics position peaked at $240K in Q1 2025.
  • 116 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2025.

Based on Verition Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.